Drugs / 177Lu-labeled-girentuximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05239533 | Feb 2022 → Mar 2027 expected | clear cell renal carcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-labeled-girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05239533 ↗ |
| Known as | 177Lu-girentuximab | “participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2” NCT05239533 ↗ |
| Modality | Monoclonal antibody | “Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab” NCT05239533 ↗ |